Instylla
Develops resorbable embolic agents for interventional oncology
H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.
biotechmedical-devices
Company facts
- Founded
- 2017
- Employees
- 70
- Headquarters
- United States
- Type
- Private
- Funding
- Series C · $21.7M · 2025
- Subsidiaries
- Embrace Hydrogel Embolic System, Tembo Embolic System
2 jobs